CUE·July 10, 2026·going-concern
Cue Biopharma Raises $50 Million in Private Placement as Going Concern Warning Persists
Cue Biopharma secured approximately $50 million through a private stock sale to fund clinical development, while its own forward-looking statement disclosures acknowledge the company still faces a going concern determination and may not have enough capital to operate beyond the next twelve months.